When to Test in Biomarker-stratified Therapy of Non-small Cell Lung Cancer – Biomarker-stratified Therapy of Non-small Cell Lung Cancer: When and What to Test?

Pneumologie. 2021 Sep;75(9):641-643. doi: 10.1055/a-1486-9057. Epub 2021 Sep 15.ABSTRACTTherapy of non-small cell lung cancer (NSCLC) should be based on biomarker test results in the palliative setting. To this end, testing of all patients in stage IV and in the future also in the earlier stages will be important. In a conference with the patronage of the German Cancer Society, the question of «reflex testing», i. e. independently of tumor stage, was discussed but not deemed to be acceptable. The current report summarizes the results of the consensus conference and discusses possible paths to efficent biomarker testing in NSCLC.PMID:34525486 | DOI:10.1055/a-1486-9057
Origen: When to Test in Biomarker-stratified Therapy of Non-small Cell Lung Cancer – Biomarker-stratified Therapy of Non-small Cell Lung Cancer: When and What to Test? – PubMed